Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 5/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.58 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | REN | P00797 | 2/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Spinorphin SCHEMBL29977609 | 1.00 | KISS1R (0.60) | KISS1RSLC6A2DPP3CAPN1CTSB | |
| Spinorphin SCHEMBL25273730 | 1.00 | KISS1R (0.60) | KISS1RSLC6A2DPP3CAPN1CTSB | |
| SCHEMBL30392074 | 0.98 | KISS1R (0.58) | KISS1RSLC6A2DPP3CAPN1CTSB | |
| SCHEMBL30392472 | 0.98 | KISS1R (0.58) | KISS1RSLC6A2DPP3CAPN1CTSB | |
| SCHEMBL30392261 | 0.94 | DPP3 (0.61) | KISS1RSLC6A2DPP3CAPN1CTSB | |
| SCHEMBL30392155 | 0.91 | CAPN1 (0.59) | KISS1RSLC6A2DPP3CAPN1CTSB | |
| SCHEMBL30844089 | 0.89 | KISS1R (0.64) | KISS1RSLC6A2OPRM1 | |
| SCHEMBL29471736 | 0.89 | SLC6A2 (0.63) | SLC6A2DPP3CAPN1CTSBOPRM1 | |
| SCHEMBL29350618 | 0.89 | SLC6A2 (0.63) | SLC6A2DPP3CAPN1CTSBOPRM1 | |
| SCHEMBL31332280 | 0.88 | KISS1R (0.64) | KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083672-A1 | FORMULATIONS AND DOSAGE AMOUNTS FOR ADMINISTERING AN ANTI-DPP3 ANTIBODY OR FRAGMENT THEREOF TO HUMANS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2025-02-20 | — | — | US | disclosed |
| US-20240385197-A1 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2024-11-21 | — | — | US | disclosed |
| EP-4197533-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | Guerin, Patrick (CH) | 2023-06-21 | — | — | EP | disclosed |
| CN-108220246-B | Compounds for improving viral transduction | 蓝鸟生物公司 | 2022-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083672-A1 | FORMULATIONS AND DOSAGE AMOUNTS FOR ADMINISTERING AN ANTI-DPP3 ANTIBODY OR FRAGMENT THEREOF TO HUMANS | DPP3, DPP4, TREH | KISS1R 4710/4885SLC6A2 372/4885DPP3 1/4885 |
| US-20240385197-A1 | METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS | DPP3, DPP4, DPP7 | KISS1R 1726/4885SLC6A2 847/4885DPP3 1/4885 |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | P2RX2, P2RX3, P2RX1 | KISS1R 473/4885SLC6A2 748/4885DPP3 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.